8TE.F CANNABIS POLAND AB ZY-10
- Market cap
- EUR 1.56M
- P/E
- -
- P/B
- 4.66x
- ROE
- -180.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 8TE.F undervalued?
Graham numberThe Graham number of CANNABIS POLAND AB ZY-10 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
CANNABIS POLAND AB ZY-10 fundamental analysis
No fundamental analysis for CANNABIS POLAND AB ZY-10 yet.
CANNABIS POLAND AB ZY-10 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About CANNABIS POLAND AB ZY-10
Cannabis Poland S.A. operates in the medical cannabis industry in Poland. It distributes and sells cannabidiol (CBD) oils and herbs, inhalers, and vaporizers, as well as dietary supplements and cosmetics for humans and animals. The company sells its products through HempWish.pl and Vapem.eu online stores. It also engages in the research and development of CBD-based drugs based on scientific council, as well as in the operation of MMedu.eu, an educational platform that provid…
Full company profileCANNABIS POLAND AB ZY-10 financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
CANNABIS POLAND AB ZY-10 annual financial statements (PLN; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 381K | 200K | 54.6K | 250K | 201K | 100K |
| Gross Profit | 30.3K | 52.3K | -49.8K | 117K | 64.1K | 18.1K |
| Operating Income | -751K | -608K | -1.27M | -2.09M | -2.36M | -2.12M |
| EBITDA | - | -636K | -1.25M | -2.16M | -2.31M | -2.61M |
| Net Income | -789K | -676K | -1.16M | -2.04M | -2.21M | -2.66M |
| EPS | -0.02 | -0.02 | -0.03 | -0.03 | -0.04 | -0.04 |
| Balance Sheet | ||||||
| Total Assets | 659K | 666K | 1.84M | 4.19M | 2.23M | 2.66M |
| Total Liabilities | 178K | 344K | 480K | 649K | 1.46M | 1.19M |
| Shareholders' Equity | 481K | 293K | 1.40M | 3.47M | 765K | 1.47M |
| Cash & Short-term Investments | 8.43K | 205K | 131K | 317K | 26.0K | 1.46M |
| Cash Flow | ||||||
| Operating Cash Flow | -931K | -357K | -1.30M | -2.11M | -2.35M | -2.98M |
| Capital Expenditure | 0.00 | 0.00 | 216K | 117K | 202K | 0.00 |
| Free Cash Flow | -931K | -357K | -1.52M | -2.23M | -2.56M | -2.98M |
| Ratios | ||||||
| ROE | -164.0% | -230.5% | -82.5% | -59.0% | -288.1% | -180.7% |
| ROA | -119.6% | -101.5% | -62.9% | -48.8% | -99.1% | -99.8% |
| Net Profit Margin | -206.9% | -338.0% | -2,117.2% | -816.7% | -1,097.0% | -2,649.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
CANNABIS POLAND AB ZY-10 dividends
CANNABIS POLAND AB ZY-10 has not paid dividends in the last 5 fiscal years.
Who owns CANNABIS POLAND AB ZY-10
- Insiders 6.97%
- Institutions 0.00%
- Public & others 93.03%
- Shares outstanding 74.4M
- Free float 63.6M
CANNABIS POLAND AB ZY-10 company profile
- Company name
- CANNABIS POLAND AB ZY-10
- Ticker
- 8TE.F
- ISIN
- PLBLOCM00013
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 3
- Fiscal year end
- December
- Address
- ul. Jana Styki 23, Warsaw, Poland, 03-928
- Phone
- 48 78 956 0105
- Website
- cp-sa.pl
About CANNABIS POLAND AB ZY-10
Cannabis Poland S.A. operates in the medical cannabis industry in Poland. It distributes and sells cannabidiol (CBD) oils and herbs, inhalers, and vaporizers, as well as dietary supplements and cosmetics for humans and animals. The company sells its products through HempWish.pl and Vapem.eu online stores. It also engages in the research and development of CBD-based drugs based on scientific council, as well as in the operation of MMedu.eu, an educational platform that provides industry-specific knowledge packages on medical marijuana. The company was formerly known as Telehorse S.A. and changed its name to Cannabis Poland S.A. in May 2019. Cannabis Poland S.A. was incorporated in 2012 and is headquartered in Warsaw, Poland.
CANNABIS POLAND AB ZY-10 management
1- Mr. Grzegorz Wladyslaw KonradMember of Management Board